Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Background CD4+ T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for KS can contribute to increasing CD4+ T cell lymphocytopenia. IL-7 is a cytokine that is essenti...
Saved in:
Main Authors: | Leonard D’Amico, Martin Cheever, Steven P Fling, Anna Wright, Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Thomas S Uldrick, Robert Yarchoan, Judith C Kaiser, Angela Shaulov Kask, Manoj P Menon, Paul Couey, Eli Burnham, Allysson Angeldekao, Byung Ha Lee, Li-Lian Kwok, Chia-Ching Jackie Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/2/e010291.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incidental Discovery of Duodenal Kaposi Sarcoma
by: Rangesh Modi, et al.
Published: (2025-01-01) -
Overexpression of NtCET4 gene in tobacco promoted vegetative bud activity and delayed flowering
by: LONG Junlan, et al.
Published: (2025-01-01) -
Time Course of Acute Hip Adduction Range of Motion Changes Following Foam Rolling
by: Anthony D’Amico, et al.
Published: (2021-04-01) -
NT5E (CD73) as a prognostic biomarker and therapeutic target associated with immune infiltration in lung adenocarcinoma
by: Leyan Chen, et al.
Published: (2025-02-01) -
Comparative Studies on the Amylase and Cellulase Production of <i>Aspergillus</i> and <i>Penicillium</i>
by: Ibatsam Khokhar, et al.
Published: (2013-05-01)